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Berlin, Berlin, Germany, 11 National Heart and Lung Institute, Imperial College London, London, United
Kingdom, 12 Centre for Evidence Synthesis in Global Health, Clinical Sciences Department, Liverpool School
of Tropical Medicine, Liverpool, United Kingdom, 13 Clinical and Experimental Sciences, University of
Southampton, Southampton, United Kingdom, 14 Tasmanian School of Medicine, University of Tasmania,
Hobart, Australia, 15 Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca,
Cambridge, United Kingdom, 16 Prioris.ai Inc, Ottawa, Canada, 17 Hindawi Ltd, London, United Kingdom,
18 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, 19 Academia
Europaea Knowledge Hub, Cardiff University, Cardiff, United Kingdom, 20 Medical Research Council,
London, United Kingdom, 21 Statistics in Anesthesiology Research (STAR) Core, Department of
Anesthesiology, College of Medicine, University of Florida, Gainesville, Florida, United States of America,
22 Discipline of Exercise and Sport Science, Faculty of Medicine and Health, University of Sydney, Sydney,
Australia, 23 National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of
America, 24 Janssen Pharmaceutica NV, Beerse, Belgium, 25 Veterinary Public Health Institute, Vetsuisse
Faculty, University of Bern, Bern, Switzerland
* nathalie.perciedusert@nc3rs.org.uk
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal
Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve
the reporting of animal research. They consist of a checklist of information to include in publi-
cations describing in vivo experiments to enable others to scrutinise the work adequately,
evaluate its methodological rigour, and reproduce the methods and results. Despite consid-
erable levels of endorsement by funders and journals over the years, adherence to the
guidelines has been inconsistent, and the anticipated improvements in the quality of report-
ing in animal research publications have not been achieved. Here, we introduce ARRIVE
2.0. The guidelines have been updated and information reorganised to facilitate their use in
practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2
sets, the “ARRIVE Essential 10,” which constitutes the minimum requirement, and the “Rec-
ommended Set,” which describes the research context. This division facilitates improved
reporting of animal research by supporting a stepwise approach to implementation. This
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helps journal editors and reviewers verify that the most important items are being reported in
manuscripts. We have also developed the accompanying Explanation and Elaboration
(E&E) document, which serves (1) to explain the rationale behind each item in the guide-
lines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through
these changes, to help ensure that researchers, reviewers, and journal editors are better
equipped to improve the rigour and transparency of the scientific process and thus
reproducibility.
See S1 Annotated Byline for individual authors’ positions at the time this article was
submitted.
Why good reporting is important
In recent years, concerns about the reproducibility of research findings have been raised by sci-
entists, funders, research users, and policy makers [1, 2]. Factors that contribute to poor repro-
ducibility include flawed study design and analysis, variability and inadequate validation of
reagents and other biological materials, insufficient reporting of methodology and results, and
barriers to accessing data [3]. The bioscience community has introduced a range of initiatives
to address the problem, from open access and open practices to enable the scrutiny of all
aspects of the research [4, 5] through to study preregistration to shift the focus towards robust
methods rather than the novelty of the results [6, 7], as well as resources to improve experi-
mental design and statistical analysis [8–10].
Transparent reporting of research methods and findings is an essential component of
reproducibility. Without this, the methodological rigour of the studies cannot be adequately
scrutinised, the reliability of the findings cannot be assessed, and the work cannot be repeated
or built upon by others. Despite the development of specific reporting guidelines for preclini-
cal and clinical research, evidence suggests that scientific publications often lack key informa-
tion and that there continues to be considerable scope for improvement [11–18]. Animal
research is a good case in point, where poor reporting impacts on the development of thera-
peutics and irreproducible findings can spawn an entire field of research, or trigger clinical
studies, subjecting patients to interventions unlikely to be effective [2, 19, 20].
In an attempt to improve the reporting of animal research, the Animal Research: Reporting
of In Vivo Experiments (ARRIVE) guidelines were published in 2010. The guidelines consist
of a checklist of the items that should be included in any manuscript that reports in vivo exper-
iments, to ensure a comprehensive and transparent description [21–30]. They apply to any
area of research using live animal species and are especially pertinent to describe comparative
research in the laboratory or other formal test setting. The guidelines are also relevant in a
wider context, for example, for observational research, studies conducted in the field, and
where animal tissues are used. In the 10 years since publication, the ARRIVE guidelines have
been endorsed by more than a thousand journals from across the life sciences. Endorsement
typically includes advocating their use in guidance to authors and reviewers. However, despite
this level of support, recent studies have shown that important information as set out in the
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ARRIVE guidelines is still missing from most publications sampled. This includes details on
randomisation (reported in only 30%–40% of publications), blinding (reported in only
approximately 20% of publications), sample size justification (reported in less than 10% of
publications), and animal characteristics (all basic characteristics reported in less than 10% of
publications) [11, 31, 32].
Evidence suggests that 2 main factors limit the impact of the ARRIVE guidelines. The first
is the extent to which editorial and journal staff are actively involved in enforcing reporting
standards. This is illustrated by a randomised controlled trial at PLOS ONE, designed to test
the effect of requesting a completed ARRIVE checklist in the manuscript submission process.
This single editorial intervention, which did not include further verification from journal staff,
failed to improve the disclosure of information in published papers [33]. In contrast, other
studies using shorter checklists (primarily focused on experimental design) with more editorial
follow-up have shown a marked improvement in the nature and detail of the information
included in publications [34–36]. It is likely that the level of resource required from journals
and editors currently prohibits the implementation of all the items of the ARRIVE guidelines.
The second issue is that researchers and other individuals and organisations responsible for
the integrity of the research process are not sufficiently aware of the consequences of incom-
plete reporting. There is some evidence that awareness of ARRIVE is linked to the use of more
rigorous experimental design standards [37]; however, researchers are often unfamiliar with
the much larger systemic bias in the publication of research and in the reliability of certain
findings and even of entire fields [33, 38–40]. This lack of understanding affects how experi-
ments are designed and grant proposals prepared, how animals are used and data recorded in
the laboratory, and how manuscripts are written by authors or assessed by journal staff, edi-
tors, and reviewers.
Approval for experiments involving animals is generally based on a harm–benefit analysis,
weighing the harms to the animals involved against the benefits of the research to society. If
the research is not reported in enough detail, even when conducted rigorously, the benefits
may not be realised, and the harm–benefit analysis and public trust in the research are under-
mined [41]. As a community, we must do better to ensure that, where animals are used, the
research is both well designed and analysed as well as transparently reported. Here, we intro-
duce the revised ARRIVE guidelines, referred to as ARRIVE 2.0. The information included
has been updated, extended, and reorganised to facilitate the use of the guidelines, helping to
ensure that researchers, editors, and reviewers—as well as other relevant journal staff—are bet-
ter equipped to improve the rigour and reproducibility of animal research.
Introducing ARRIVE 2.0
In ARRIVE 2.0, we have improved the clarity of the guidelines, prioritised the items, added
new information, and generated the accompanying Explanation and Elaboration (E&E) docu-
ment to provide context and rationale for each item [42] (also available at https://www.
arriveguidelines.org). New additions comprise inclusion and exclusion criteria, which are a
key aspect of data handling and prevent the ad hoc exclusion of data [43]; protocol registration,
a recently emerged approach that promotes scientific rigour and encourages researchers to
carefully consider the experimental design and analysis plan before any data are collected [44];
and data access, in line with the FAIR Data Principles [45] (Findable, Accessible, Interopera-
ble, and Reusable). S1 Table summarises the changes.
The most significant departure from the original guidelines is the classification of items
into 2 prioritised groups, as shown in Tables 1 and 2. There is no ranking of the items within
each group. The first group is the “ARRIVE Essential 10,” which describes information that is
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the basic minimum to include in a manuscript, as without this information, reviewers and
readers cannot confidently assess the reliability of the findings presented. It includes details on
the study design, the sample size, measures to reduce subjective bias, outcome measures, statis-
tical methods, the animals, experimental procedures, and results. The second group, referred
Table 1. ARRIVE Essential 10.
ARRIVE Essential 10
Study design 1 For each experiment, provide brief details of study design including:
a. The groups being compared, including control groups. If no control group has
been used, the rationale should be stated.
b. The experimental unit (e.g., a single animal, litter, or cage of animals).
Sample size 2 a. Specify the exact number of experimental units allocated to each group, and the
total number in each experiment. Also indicate the total number of animals used.
b. Explain how the sample size was decided. Provide details of any a priori sample
size calculation, if done.
Inclusion and exclusion
criteria
3 a. Describe any criteria used for including and excluding animals (or experimental
units) during the experiment, and data points during the analysis. Specify if these
criteria were established a priori. If no criteria were set, state this explicitly.
b. For each experimental group, report any animals, experimental units, or data
points not included in the analysis and explain why. If there were no exclusions,
state so.
c. For each analysis, report the exact value of n in each experimental group.
Randomisation 4 a. State whether randomisation was used to allocate experimental units to control
and treatment groups. If done, provide the method used to generate the
randomisation sequence.
b. Describe the strategy used to minimise potential confounders such as the order
of treatments and measurements, or animal/cage location. If confounders were not
controlled, state this explicitly.
Blinding 5 Describe who was aware of the group allocation at the different stages of the
experiment (during the allocation, the conduct of the experiment, the outcome
assessment, and the data analysis).
Outcome measures 6 a. Clearly define all outcome measures assessed (e.g., cell death, molecular markers,
or behavioural changes).
b. For hypothesis-testing studies, specify the primary outcome measure, i.e., the
outcome measure that was used to determine the sample size.
Statistical methods 7 a. Provide details of the statistical methods used for each analysis, including
software used.
b. Describe any methods used to assess whether the data met the assumptions of the
statistical approach, and what was done if the assumptions were not met.
Experimental animals 8 a. Provide species-appropriate details of the animals used, including species, strain
and substrain, sex, age or developmental stage, and, if relevant, weight.
b. Provide further relevant information on the provenance of animals, health/
immune status, genetic modification status, genotype, and any previous
procedures.
Experimental procedures 9 For each experimental group, including controls, describe the procedures in
enough detail to allow others to replicate them, including:
a. What was done, how it was done, and what was used.
b. When and how often.
c. Where (including detail of any acclimatisation periods).
d. Why (provide rationale for procedures).
Results 10 For each experiment conducted, including independent replications, report:
a. Summary/descriptive statistics for each experimental group, with a measure of
variability where applicable (e.g., mean and SD, or median and range).
b. If applicable, the effect size with a confidence interval.
Explanations and examples for items 1 to 10 are available in the E&E document [42] and on the website at https://
www.arriveguidelines.org.
Abbreviations: ARRIVE, Animal Research: Reporting of In Vivo Experiments; E&E, Explanation and Elaboration
https://doi.org/10.1371/journal.pbio.3000410.t001
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to as the “Recommended Set,” adds context to the study described. This includes the ethical
statement, declaration of interest, protocol registration, and data access, as well as more
detailed information on the methodology such as animal housing, husbandry, care, and moni-
toring. Items on the abstract, background, objectives, interpretation, and generalisability also
describe what to include in the more narrative parts of a manuscript.
Revising the guidelines has been an extensive and collaborative effort, with input from the
scientific community carefully built into the process. The revision of the ARRIVE guidelines
has been undertaken by an international working group—the authors of this publication—
with expertise from across the life sciences community, including funders, journal editors, stat-
isticians, methodologists, and researchers from academia and industry. We used a Delphi exer-
cise [46] with external stakeholders to maximise diversity in fields of expertise and
geographical location, with experts from 19 countries providing feedback on each item, sug-
gesting new items, and ranking items according to their relative importance for assessing the
Table 2. ARRIVE Recommended Set.
Recommended Set
Abstract 11 Provide an accurate summary of the research objectives, animal species, strain
and sex, key methods, principal findings, and study conclusions.
Background 12 a. Include sufficient scientific background to understand the rationale and
context for the study, and explain the experimental approach.
b. Explain how the animal species and model used address the scientific
objectives and, where appropriate, the relevance to human biology.
Objectives 13 Clearly describe the research question, research objectives and, where
appropriate, specific hypotheses being tested.
Ethical statement 14 Provide the name of the ethical review committee or equivalent that has
approved the use of animals in this study, and any relevant licence or protocol
numbers (if applicable). If ethical approval was not sought or granted, provide a
justification.
Housing and husbandry 15 Provide details of housing and husbandry conditions, including any
environmental enrichment.
Animal care and monitoring 16 a. Describe any interventions or steps taken in the experimental protocols to
reduce pain, suffering, and distress.
b. Report any expected or unexpected adverse events.
c. Describe the humane endpoints established for the study, the signs that were
monitored, and the frequency of monitoring. If the study did not have humane
endpoints, state this.
Interpretation/scientific
implications
17 a. Interpret the results, taking into account the study objectives and hypotheses,
current theory, and other relevant studies in the literature.
b. Comment on the study limitations, including potential sources of bias,
limitations of the animal model, and imprecision associated with the results.
Generalisability/translation 18 Comment on whether, and how, the findings of this study are likely to
generalise to other species or experimental conditions, including any relevance
to human biology (where appropriate).
Protocol registration 19 Provide a statement indicating whether a protocol (including the research
question, key design features, and analysis plan) was prepared before the study,
and if and where this protocol was registered.
Data access 20 Provide a statement describing if and where study data are available.
Declaration of interests 21 a. Declare any potential conflicts of interest, including financial and
nonfinancial. If none exist, this should be stated.
b. List all funding sources (including grant identifier) and the role of the
funder(s) in the design, analysis, and reporting of the study.
Together with the Essential 10, the Recommended Set represents best reporting practice. Explanations and examples
for items 11 to 21 are available in the E&E document [42] and on the website https://www.arriveguidelines.org.
Abbreviations: ARRIVE, Animal Research: Reporting of In Vivo Experiments; E&E, Explanation and Elaboration
https://doi.org/10.1371/journal.pbio.3000410.t002
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reliability of research findings. This ranking resulted in the prioritisation of the items of the
guidelines into the 2 sets. Demographics of the Delphi panel and full methods and results are
presented in Supporting Information S1 Delphi and S1 Data. Following their publication on
BioRxiv, the revised guidelines and the E&E were also road tested with researchers preparing
manuscripts describing in vivo studies, to ensure that these documents were well understood
and useful to the intended users. This study is presented in Supporting Information S1 Road
Testing and S2 Data.
While reporting animal research in adherence to all 21 items of ARRIVE 2.0 represents best
practice, the classification of the items into 2 groups is intended to facilitate the improved
reporting of animal research by allowing an initial focus on the most critical issues. This better
allows journal staff, editors, and reviewers to verify that the items have been adequately
reported in manuscripts. The first step should be to ensure compliance with the ARRIVE
Essential 10 as a minimum requirement. Items from the Recommended Set can then be added
over time and in line with specific editorial policies until all the items are routinely reported in
all manuscripts. ARRIVE 2.0 are fully compatible with and complementary to other guidelines
that have been published in recent years. By providing a comprehensive set of recommenda-
tions that are specifically tailored to the description of in vivo research, they help authors
reporting animal experiments adhere to the National Institutes of Health (NIH) standards [43]
and the minimum standards framework and checklist (Materials, Design, Analysis and
Reporting [MDAR] [47]). The revised guidelines are also in line with many journals’ policies
and will assist authors in complying with information requirements on the ethical review of
the research [48, 49], data presentation and access [50–52], statistical methods [51, 52], and
conflicts of interest [53, 54].
Although the guidelines are written with researchers and journal editorial policies in mind,
it is important to stress that researchers alone should not have to carry the responsibility for
transparent reporting. Funders, institutions, and publishers’ endorsement of ARRIVE has
been instrumental in raising awareness to date; they now have a key role to play in building
capacity and championing the behavioural changes required to improve reporting practices.
This includes embedding ARRIVE 2.0 in appropriate training, workflows, and processes to
support researchers in their different roles. While the primary focus of the guidelines has been
on the reporting of animal studies, ARRIVE also has other applications earlier in the research
process, including in the planning and design of in vivo experiments. For example, requesting
a description of the study design in line with the guidelines in funding or ethical review appli-
cations ensures that steps to minimise experimental bias are considered at the beginning of the
research cycle [55].
Conclusion
Transparent reporting is clearly essential if animal studies are to add to the knowledge base
and inform future research, policy, and clinical practice. ARRIVE 2.0 prioritises the reporting
of information related to study reliability. This enables research users to assess how much
weight to ascribe to the findings and, in parallel, promotes the use of rigorous methodology in
the planning and conduct of in vivo experiments [37], thus increasing the likelihood that the
findings are reliable and, ultimately, reproducible.
The intention of ARRIVE 2.0 is not to supersede individual journal requirements but to
promote a harmonised approach across journals to ensure that all manuscripts contain the
essential information needed to appraise the research. Journals usually share a common objec-
tive of improving the methodological rigour and reproducibility of the research they publish,
but different journals emphasise different pieces of information [56–58]. Here, we propose an
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expert consensus on information to prioritise. This will provide clarity for authors, facilitate
transfer of manuscripts between journals, and accelerate an improvement of reporting
standards.
Concentrating the efforts of the research and publishing communities on the ARRIVE
Essential 10 items provides a manageable approach to evaluate reporting quality efficiently and
assess the effect of interventions and policies designed to improve the reporting of animal
experiments. It provides a starting point for the development of operationalised checklists to
assess reporting, ultimately leading to the build of automated or semi-automated artificial
intelligence tools that can detect missing information rapidly [59].
Improving reporting is a collaborative endeavour, and concerted effort from the biomedical
research community is required to ensure maximum impact. We welcome collaboration with
other groups operating in this area, as well as feedback on ARRIVE 2.0 and our implementa-
tion strategy.
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